Newsroom

Home/Newsroom/

First-Line Imatinib More Effective Than Widely Believed – LRG Science

The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.

By |2019-12-13T10:07:51-05:00December 13th, 2019|Drug Treatment, Gleevec, LRG Science, News|

GIST Mentor Training Day Photo Gallery

The LRG held a GIST Mentor training day in our offices in Wayne, NJ, in October 2019. The gallery includes photos of the new GIST Mentors, LRG staff. One of the training days was on Halloween so some of the staff dressed up. These photos were taken by David Josephy of Life Raft Group Canada.

By |2019-11-14T10:07:55-05:00November 7th, 2019|Events, LRG Gallery|

Accelerating Innovation in Precision Medicine

Sara Rothschild, VP Programs and Services at the LRG, attended an executive education program at the Harvard Business School which brought together leaders from the health care, scientific, technological, and business communities to speed progress and drive cures.

By |2019-12-19T11:25:32-05:00November 3rd, 2019|News, Survival Strategies|